Video

Initial Efficacy and Safety of RP1 + Nivolumab in Patients With Anti–PD-1–Failed Melanoma From the Ongoing Phase 1/2 IGNYTE Study

Author(s):

Michael B. Atkins, MD, Georgetown Lombardi Comprehensive Cancer Center

Expert Michael Atkins, MD, reviews data from the ongoing IGNYTE study utilizing RP1 in combination with nivolumab in relapsed/refractory melanoma.

Related Videos
BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical, and the C797S Resistance Mutation To Address The Evolved Landscape Of EGFR Mutant NSCLC
BTK Inhibitors in CLL : Second Generation Drugs and Beyond
Zeynep Eroglu, MD
Zeynep Eroglu, MD
Zeynep Eroglu, MD
Zeynep Eroglu, MD
PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse
Daniel Olson, MD
Related Content
Panos Papachristou, MD, PhD, of Karolinska Institutet
May 24th 2024

AI Support Tool Demonstrates Detection Utility for Melanoma at Primary Care Practices

Jeffrey S. Weber, MD, PhD
November 6th 2023

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

Mitchell Fane, PhD
May 22nd 2024

Fox Chase Researcher Mitchell Fane Awarded $255,000 Grant to Explore Relationship Between Aging and Melanoma

Nikhil I. Khushalani, MD; Martin F. Dietrich, MD, PhD; Jason J. Luke, MD, FACP; Vishal A. Patel, MD, FAAD, FACMS
March 6th 2023

CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice

Melanoma | Image Credit: © SciePro - stock.adobe.com
May 2nd 2024

Adjuvant Multipeptide Vaccine Combination Prolongs Survival in Melanoma

Immunotherapy Resistance in Uveal Melanoma | Image Credit: © David A Litman - stock.adobe.com
May 1st 2024

Immunogenomics Demonstrate Predictive Capability to Immunotherapy Resistance in Uveal Melanoma